financetom
Business
financetom
/
Business
/
Calibre Mining Declines 8%, TD Maintains Buy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Calibre Mining Declines 8%, TD Maintains Buy
Mar 20, 2024 9:14 AM

11:53 AM EDT, 03/20/2024 (MT Newswires) -- Calibre Mining Corp. ( CXBMF ) declined 8% on Wednesday.

The Vancouver-based mining company announced a $100 Million bought deal financing after market close on Tuesday.

"We believe this financing should not come as significant surprise given the significant capital required for the ongoing construction of Valentine, which is expected to come on-line in H1/25," TD Securities analyst Steven Green said in a note to clients.

"We believe additional funds were required to continue drawing on the Sprott debt facility," Green said in a note to clients. "As we understand it, the restricted cash cannot be accessed without Calibre being fully funded to build Valentine."

"Capital cost overruns continue to be a risk on new projects," the analyst said.

Green maintained a Buy rating and $2.50 price target on Calibre shares.

The stock declined $0.145, or 8%, to $1.66 on the Toronto Stock Exchange.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Price: 1.67, Change: -0.14, Percent Change: -8.01

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lyft's slower-than-expected revenue growth clouds upbeat bookings forecast
Lyft's slower-than-expected revenue growth clouds upbeat bookings forecast
Nov 5, 2025
(Reuters) -Lyft ( LYFT ) reported third-quarter revenue growth a tad below Wall Street expectations on Wednesday amid intense competition in its core North American markets, overshadowing an upbeat bookings forecast for the holiday travel season. Shares of the San Francisco-based company fell about 3% in extended trading. The company has benefited from its recent push into international markets and...
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Cardiac muscle therapeutics firm Cytokinetics Q3 net loss widens
Nov 5, 2025
Overview * Cytokinetics ( CYTK ) Q3 net loss widens to $306.2 mln, driven by debt conversion expense * Company reports Q3 revenue of $1.9 mln, up from $0.5 mln last year * Cytokinetics ( CYTK ) prepares for potential U.S. launch of aficamten pending FDA approval Outlook * Company expects EMA decision on aficamten MAA in 1H 2026 *...
Delaware judge says she will not block Metsera from ending Pfizer deal 
Delaware judge says she will not block Metsera from ending Pfizer deal 
Nov 5, 2025
WILMINGTON, Delaware, Nov 5 (Reuters) - A Delaware judge said on Wednesday she would reject a request by Pfizer ( PFE ) to temporarily block Metsera ( MTSR ) from terminating its takeover deal with Pfizer ( PFE ), allowing Metsera ( MTSR ) to proceed instead with a higher $10 billion deal from Novo Nordisk. ...
Jazz Pharmaceuticals Q3 revenue beats estimates
Jazz Pharmaceuticals Q3 revenue beats estimates
Nov 5, 2025
Overview * Jazz Pharmaceuticals ( JAZZ ) Q3 revenue grows 7% yr/yr, beating analyst expectations * Adjusted EPS for Q3 beats consensus, reflecting robust operational performance * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln Outlook * Company narrows 2025 revenue guidance to $4.175 - $4.275 bln * Jazz Pharmaceuticals ( JAZZ ) expects top-line data from zanidatamab...
Copyright 2023-2026 - www.financetom.com All Rights Reserved